Comparative Pharmacology
Head-to-head clinical analysis: ABSTRAL versus ARYNTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABSTRAL versus ARYNTA.
ABSTRAL vs ARYNTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
ARYNTA (pembrolizumab) is a humanized monoclonal antibody that binds to the programmed death-1 (PD-1) receptor on T cells, blocking its interaction with PD-L1 and PD-L2, thereby restoring anti-tumor immune responses.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
400 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Terminal elimination half-life is 2-4 hours in healthy adults, prolonged to 6-12 hours in moderate to severe renal impairment (CrCl <30 mL/min).
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Primarily renal elimination (70-80% unchanged), with 10-15% fecal excretion via biliary secretion.
Category C
Category C
Opioid Analgesic
Opioid Analgesic